

MAGLUMI® FSH (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of FSH in human serum with the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer (including Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 1000 Plus, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3 and MAGLUMI X6) and Biolumi series Integrated System (including Biolumi CX8).

SUMMARY AND EXPLANATION OF THE TEST

Human follicle stimulating hormone (hFSH) is a glycoprotein of approximately 30,000 daltons which is made up of two non-identical, covalently-associated glycoprotein subunits, denoted alpha and beta. The alpha subunit is similar in structure for the glycoproteins hFSH, hCG, hLH, and hTSH. The beta subunit of FSH is contributed to immunological and physiological specificity.¹⁻³

Follicle-stimulating hormone (FSH) is secreted by the pituitary gland in the brain.

In women, FSH stimulates the growth and maturation of follicles in the ovaries during the follicular phase of the menstrual cycle⁴. The menstrual cycle is divided into the follicular and the luteal phases, characterized by a mid-cycle surge of FSH and luteinizing hormone (LH)^{5,6}. Ovulation occurs shortly after this mid-cycle surge of hormones. During the follicular phase, FSH initiates the production of estradiol by the follicle, and the two hormones work together in the further development of the follicle. During the luteal phase, FSH stimulates the production of progesterone⁷. Both estradiol and progesterone help the pituitary control the amount of FSH produced. FSH also facilitates the ability of the ovary to respond to LH. At the time of menopause, the ovaries stop functioning and FSH levels rise. In men, FSH stimulates the testes to produce mature sperm and also promotes the production of androgen binding proteins. FSH levels are relatively constant in males after puberty^{8,9}.

FSH is often used in conjunction with other tests (LH, testosterone, estradiol, and progesterone) in the workup of infertility in both men and women. FSH levels are used to help determine the cause of low sperm count. FSH levels are also useful in the investigation of menstrual irregularities and to aid in the diagnosis of pituitary disorders or diseases involving the ovaries or testes.

PRINCIPLE OF THE TEST

The FSH assay is a sandwich chemiluminescence immunoassay.

The sample (or calibrator/control, if applicable), magnetic microbeads coated with anti-FSH monoclonal antibody, ABEI labeled with another monoclonal antibody are mixed thoroughly and incubated, forming sandwich complexes. After precipitation in a magnetic field, the supernatant is decanted and then perform a wash cycle. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of FSH present in the sample (or calibrator/control, if applicable).

KIT COMPONENTS

Material Provided

Components	Contents	100 tests (REF: 130202001M)	50 tests (REF: 130602001M)
Magnetic Microbeads	Magnetic microbeads coated with anti-FSH monoclonal antibody, containing BSA, NaN ₃ (<0.1%).	2.5 mL	2.0 mL
Calibrator Low	Containing bovine serum and FSH antigen, NaN ₃ (<0.1%).	2.5 mL	2.0 mL
Calibrator High	Containing bovine serum and FSH antigen, NaN ₃ (<0.1%).	2.5 mL	2.0 mL
ABEI Label	Anti-FSH monoclonal antibody labeled with ABEI, containing BSA, NaN ₃ (<0.1%).	10.5 mL	7.0mL
Internal Quality Control	Containing bovine serum and FSH antigen, NaN ₃ (<0.1%).	2.0 mL	2.0 mL

All reagents are provided ready-to-use.

Accessories Required But Not Provided

MAGLUMI and Biolumi Series:

Reaction Module	REF: 630003
Starter 1+2	REF: 130299004M, 130299027M
Wash Concentrate	REF: 130299005M
Light Check	REF: 130299006M
Reaction Cup	REF: 130105000101

Please order accessories from Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) or our authorized representatives.

CALIBRATION

Traceability: This method has been standardized against WHO 1st International Standard 92/510.

Test of assay specific calibrators allows the RLU values to adjust the assigned master curve. Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve (10 calibrations) provided via the reagent Radio Frequency Identification (RFID) CHIP.

Recalibration is recommended if any of the following conditions occurs:

- After each change of lots (Reagent or Starter 1+2).
- Every 4 weeks and/or each time a new reagent kit is used (recommended).
- After instrument service is required.
- If control results lie outside the expected range.

QUALITY CONTROL

Follow government regulations or accreditation requirements for quality control frequency.

Internal quality control is only applicable with MAGLUMI and Biolumi systems. For instructions for use and target value refer to **FSH (CLIA) Quality Control Information**. User needs to judge results with their own standards and knowledge.

For detailed information about entering quality control values, refer to the corresponding Analyzer Operating Instructions.

To monitor system performance and chart trends, commercially available quality control materials are required. Treat all quality control samples the same as patient samples. A satisfactory level of performance is achieved when analyte values obtained are within the acceptable Control Range for the system or within your range, as determined by an appropriate internal laboratory quality control scheme. If the quality control results do not fall within the Expected Values or within the laboratory's established values, do not report results. Take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the instructions for use.
- Rerun the assay with fresh quality control samples.
- If necessary, contact your local technical supporters or distributors for assistance.

SPECIMEN COLLECTION AND PREPARATION

- Use standard sampling tubes or tubes containing separating gel. Collect blood aseptically following the universal precautions for venipuncture.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time.
- If the specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results. Samples must be free of fibrin and other particulate matter.
- Do not use hemolyzed or grossly lipemic specimens as well as specimens containing particulate substance or exhibiting obvious microbial contamination. Inspect all specimens for bubbles, and remove bubbles before analysis for optimal results.
- Avoid repeating freeze-thaw cycles. The serum sample can be only frozen and thawed one time. Specimens must be mixed thoroughly after thawing.
- Centrifuged specimens with a lipid layer on the top must be transferred to a sample cup or a secondary tube. Care should be taken to transfer only the clarified specimen without the lipemic material.
- All samples (patient specimens and controls) should be tested within 3 hours when placed on board the MAGLUMI and Biolumi Systems. Refer to the SNIBE service for more details of onboard sample storage constraints.
- Specimens removed from the separator, cells or clot may be stored up to 24 hours at 2-8°C. Freeze samples at or below -20°C if the sample is not assayed within 24 hours.
- Before shipping specimens, it is recommended that specimens be removed from the serum separator, red blood cells or clot. When shipped, specimens should be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens should be shipped frozen.
- The sample volume required for a single determination of FSH is 40 µL.

WARNING AND PRECAUTIONS FOR USERS

- **IVD**
- For *In Vitro* Diagnostic Use.
- Follow the package insert carefully. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Safety Precautions

- **CAUTION:** This product requires the handling of human specimens. It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the 29 CFR 1910.1030 Occupational exposure to bloodborne pathogens. Biosafety Level 2 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- All samples, biological reagents and materials used in the assay should be considered potentially able to transmit infectious agents. They should therefore be disposed in accordance with the practices of your institution. Discard all materials in a safe and acceptable manner and in compliance with prevailing regulatory requirements.
- This product contains Sodium Azide. Dispose of contents and containers must be in accordance with all local, regional and national regulations.
- Refer to safety data sheets which are available on request.

Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not interchange reagent components from different reagents or lots.
- Prior to loading the reagent kit on the system for the first time, the reagent kit requires mixing to re-suspend magnetic microbeads that have settled during shipment.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and samples.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts which have no effect on assay efficacy.
- For detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

STORAGE AND STABILITY

- Sealed: Stored at 2-8°C until the expiration date.
- Opened at 2-8°C: Minimum stability is 4 weeks.
- On-board: Minimum stability is 4 weeks.
- To ensure the best kit performance, it is recommended to place opened kits in the refrigerator after the end of the intraday test work. It is still possible to keep on using the kit beyond the opened or on-board period if the controls are found within the expected ranges.
- Keep upright for storage to facilitate later proper resuspension of magnetic microbeads.
- Keep away from sunlight.

TEST PROCEDURE

Preparation of the Reagent

- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.
- To ensure proper test performance, strictly adhere to the corresponding Analyzer Operating Instructions. Each test parameter is identified via a RFID CHIP on the Reagent kit. For further information please refer to the corresponding Analyzer Operating Instructions.

DILUTION

Sample dilution by analyzer is not available in this reagent kit.

Samples with concentrations above the measuring range can be diluted manually. After manual dilution, multiply the result by the dilution factor.

Please choose applicable diluents or ask SNIBE for advice before manual dilution.

High-Dose Hook

For the FSH assay, no high dose hook effect was observed when samples containing FSH up to 3,000 mIU/mL.

LIMITATIONS

- A skillful technique and strict adherence to the instructions are necessary to obtain reliable results.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.
- A result within the expected range does not rule out the presence of disease and should be interpreted together with other diagnostic procedures.
- Test results are reported quantitatively. However, diagnosis of a disease should not be based on the result of a single test, but should be determined in conjunction with clinical findings in association with medical judgement.
- Any therapeutical decision should also be taken on a case-by-case basis.
- Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

RESULTS

Calculation of Results

The analyzer automatically calculates the FSH concentration of each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are reported in the unit of mIU/mL. For further information please refer to the corresponding Analyzer Operating Instructions.

Interpretation of Results

The expected ranges for the FSH assay were obtained by testing 271 apparently healthy individuals (115 males and 156 females) in China and gave the following expected values:

Males: 1.5-11.8 mIU/mL (2.5th-97.5th percentiles).

Females:

Phase	N	2.5 th -97.5 th percentiles (mIU/mL)
Follicular phase	45	3.2-15
Ovulatory phase	30	7.5-20
Luteal phase	46	1.3-11
Postmenopause	35	36-138

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

Precision

Precision for the FSH assay was determined as described in the CLSI EP5-A2. 3 human serum pools and 2 controls containing different concentration of analyte were assayed in duplicate at two independent runs per day for 20 testing days. The results are summarized in the following table:

Sample	Mean(mIU/mL) (N=80)	Within-Run		Between-Run		Total	
		SD(mIU/mL)	%CV	SD(mIU/mL)	%CV	SD(mIU/mL)	%CV
Serum Pool 1	2.184	0.154	7.05	0.000	0.00	0.154	7.05
Serum Pool 2	12.061	0.576	4.78	0.410	3.40	0.707	5.86
Serum Pool 3	123.539	3.439	2.78	4.903	3.97	5.989	4.85
Control 1	18.242	0.867	4.75	0.711	3.90	1.121	6.15
Control 2	184.672	4.502	2.44	7.255	3.93	8.538	4.62

Limit of Blank (LoB)

The LoB for the FSH assay is 0.1 mIU/mL.

Limit of Detection (LoD)

The LoD for the FSH assay is 0.2 mIU/mL.

Measuring Range

0.1-400 mIU/mL (defined by the limit of blank and the maximum of the master curve). Values below the limit of blank are reported as <0.1 mIU/mL. Values above the measuring range are reported as >400 mIU/mL.

Linearity

The assay is linear between 0.2 mIU/mL and 400 mIU/mL based on a study performed with guidance from CLSI EP6-A. Nine equally distributed levels of samples were prepared by blending a serum sample containing FSH 420 mIU/mL with a serum sample depleted of FSH (0.0 mIU/mL). The mean sample recovery ranged from 90% to 110%.

Method Comparison

A total of 111 samples in the range of 1.151 to 379.404 mIU/mL were tested by the FSH assay (y) and a commercially available immunoassay (x). The data from the resulting linear regressions are summarized as: $y=0.973x-2.0872$, $r^2=0.9683$.

Analytical Specificity

The specificity of the assay was obtained by adding LH (200 mIU/mL), HCG (5000 mIU/mL), and TSH (2000 µIU/mL) to serum samples at the indicated concentrations. No interference was found.

Endogenous Interference

Substances up to the following concentrations did not interfere with the assay:

- Bilirubin 64 mg/dL
- Hemoglobin 1000 mg/dL
- Triglyceride 2000 mg/dL


REFERENCES

1. Vaitukaitis JL and Ross GT. Antigenic similarities among the human glycoprotein hormones and their subunits. In Gonadotropins, 1972; Edited by Saxena BB, Gandy HM and Beling CG. New York, NY: John Wiley and Sons, 435-443.
2. Pierce JG and Parsons TF. Glycoprotein hormones: structure and function. Annual Review of Biochemistry, 1981;50: 465-495.
3. South SA, Yankov VI, Evans WS. Normal reproductive neuroendocrinology in the female. In Endocrinology and Metabolism Clinics of North America 1993; Edited by Veldhuis JD, Philadelphia, PA: W.B. Saunders Co. 22: 1-28.
4. Adashi EY. The ovarian life cycle. In Reproductive Endocrinology. Edited by Yen SSC and Jaffe RB. Philadelphia, PA: WB Saunders Co., 1992; 22: 1-28.
5. Daughaday WH. The Adenohypophysis. In: Wilson JD, Foster DW, editors. Williams Textbook of Endocrinology. Philadelphia: Saunders, 1985:568-613.
6. Bonnar J. Gynaecology and Obstetrics: The Hypothalamus and Reproductive Function. In: Scott RB and Walker RM, editors. The Medical Annual. Bristol (England): J Wright and Sons, 1973:251-8.
7. Runnebaum B, Rabe T. Gynäkologische Endokrinologie und Fortpflanzungsmedizin Springer Verlag 1994. Band 1:17,253-255, Band 2:152-154,360,348. ISBN 3-540-57345-3, ISBN 3-540-57347-X.
8. Schmidt-Mathiesen H. Gynäkologie und Geburtshilfe. Schattauer Verlag 1992.
9. Scott MG, Ladenson JH, Green ED, et al. Hormonal evaluation of female infertility and reproductive disorders. Clin Chem 1989;35:620-630.



Shenzhen New Industries Biomedical Engineering Co., Ltd.













No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
Tel: +86-755-21536601 Fax: +86-755-28292740



Shanghai International Holding Corp. GmbH (Europe)

Eiffestrasse 80, 20537 Hamburg, Germany
Tel: +49-40-2513175 Fax: +49-40-255726

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8 °C)		Use-by date
	Contains sufficient for		Keep away from sunlight
	This way up		Authorized representative in the European Community
	<i>In vitro</i> diagnostic medical device		Kit components
	Catalogue number		Batch code